Veritas In Silico (130A) · TargetFirst statedLatest Share Issuance and Disposal (2026-10-13): "Restated"
Create one proprietary pipeline candidate each year
First written in FY2025. 1 of 2 entries say "Restated". Latest entry: 2026-10-13.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Continuous creation of new drugs and pipeline expansionA theme 17 companies write about · 0 as a headwind · 23 as a tailwind
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 17 companies compared. The sentences above are computed from all 17.Full recordFilings, disclosures and news, newest first
- 2026-10-13RestatedShare Issuance and Disposal
「2025年度創出の「p53遺伝子をターゲットとする急性腎不全の予防薬」、2026年度創出の「lncRNA H19遺伝子を標的とするがん治療薬」に続き、毎年1本ペースで創出されるパイプライン開発を着実に進めることに活用します。」
毎年1本の自社パイプライン創出方針を再掲し、パイプライン1・2に続く開発継続を資金使途と結び付けている。 - FY2025First statedAnnual report
「In the pipeline business, we plan to create 1 pipeline each year from FY2025 onward while leveraging the aibVIS platform, one of our strengths.」
For the pipeline business under the hybrid model, the company disclosed for the first time a KPI and plan to create 1 in-house pipeline each year from FY2025 onward using the aibVIS platform.